| 1 | Combination Hormonal Drug Therapy Inhibits In Vitro Growth of Adult Ovarian Granulosa Tumor Cells. (Summey RM, Iden M, Tsaih SW, Schmidt R, Parashar D, Wang S, Rader JS, Hopp E) Cancer Invest 2026 Mar;44(3):279-295 |
| 1 | Long-Term Results of NRG/RTOG 9601, a Randomized Trial of Radiation With or Without Antiandrogens in Patients Receiving Salvage Prostate Bed Radiation Therapy Postprostatectomy. (Lukka HR, Pugh SL, Shipley WU, Major PP, Sartor O, Dayes IS, Bahary JP, Efstathiou JA, Pisansky TM, Zeitzer KL, Lawton CAF, Dess RT, Camarata AS, Balogh AG, Souhami L, Rosenthal SA, Pennington JD, Seiferheld WF, Feng FY, Sandler HM) Int J Radiat Oncol Biol Phys 2025 Nov 15;123(4):990-999 4 Citations |
| 1 | Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy. (Chan E, Pugh SL, Simko JP, Feng F, Shipley WU, Lukka HR, Bahary JP, Pisansky TM, Zeitzer KL, Gore E, Efstathiou JA, Rosenthal SA, Balogh AG, Lovett RD, Wong A, Dess RT, McGinnis LS, Kuettel M, DeMora L, Sandler HM) Prostate 2025 Oct;85(14):1315-1322 1 Citation |
| 1 | Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. (Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, Thompson DJS, Das R, Dignam JJ, Sweeney C, Attard G, Bahary JP, Lukka HR, Hall WA, Pisansky TM, Shah AB, Pugh SL, Shipley WU, Tran PT) JAMA Oncol 2021 Apr 01;7(4):544-552 129 Citations |
| 1 | Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs. (Luginina A, Gusach A, Marin E, Mishin A, Brouillette R, Popov P, Shiriaeva A, Besserer-Offroy É, Longpré JM, Lyapina E, Ishchenko A, Patel N, Polovinkin V, Safronova N, Bogorodskiy A, Edelweiss E, Hu H, Weierstall U, Liu W, Batyuk A, Gordeliy V, Han GW, Sarret P, Katritch V, Borshchevskiy V, Cherezov V) Sci Adv 2019 Oct;5(10):eaax2518 85 Citations |
| 1 | Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. (Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM) Cancer 2017 Jul 01;123(13):2489-2496 17 Citations |
| 1 | Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. (Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, NRG Oncology RTOG) N Engl J Med 2017 Feb 02;376(5):417-428 587 Citations |
| 1 | Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. (Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM) J Clin Oncol 2015 Feb 01;33(4):332-9 120 Citations |
| 1 | Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. (Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group) BJU Int 2010 Apr;105(8):1074-81 98 Citations |
| 1 | The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer. (See WA, Tyrrell CJ, CASODEX Early Prostate Cancer Trialists' Group) J Cancer Res Clin Oncol 2006 Aug;132 Suppl 1(Suppl 1):S7-16 57 Citations |
| 1 | The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median followup. (McLeod DG, See WA, Klimberg I, Gleason D, Chodak G, Montie J, Bernstein G, Morris C, Armstrong J) J Urol 2006 Jul;176(1):75-80 41 Citations |
| 1 | Are bone scans necessary in men with low prostate specific antigen levels following localized therapy? (Warren KS, Chodak GW, See WA, Iverson P, McLeod D, Wirth M, Morris C, Armstrong J) J Urol 2006 Jul;176(1):70-3; discussion 73-4 12 Citations |
| 1 | Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. (McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, Casodex Early Prostate Cancer Trialists' Group) BJU Int 2006 Feb;97(2):247-54 256 Citations |
| 1 | Bicalutamide ('Casodex') 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. (Tyrrell CJ, Payne H, See WA, McLeod DG, Wirth MP, Iversen P, Armstrong J, Morris C, 'Casodex' Early Prostate Cancer Trialists Group) Radiother Oncol 2005 Jul;76(1):4-10 62 Citations |
| 1 | Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. (Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group) J Urol 2004 Nov;172(5 Pt 1):1865-70 201 Citations |
| 1 | Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program. (Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson JE, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group) Urology 2004 May;63(5):928-33 16 Citations |
| 2 | Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines. (Chen F, Langenstroer P, Zhang G, Iwamoto Y, See W) J Urol 2003 Nov;170(5):2009-13 45 Citations |
| 1 | Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. (See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ, Casodex Early Prostate Cancer Trialist Group) J Urol 2002 Aug;168(2):429-35 214 Citations |
| 1 | Arachidonylethanolamide (anandamide) binds with low affinity to dihydropyridine binding sites in brain membranes. (Jarrahian A, Hillard CJ) Prostaglandins Leukot Essent Fatty Acids 1997 Dec;57(6):551-4 24 Citations |
